OGN vs TXG · P/E 3.4, rev $3.02B vs rev $301.9M
Organon & Co (OGN) versus 10X Genomics Inc (TXG) — a side-by-side from cached financials, not a winner call.
Organon & Co (OGN) is a drug manufacturers - general company listed on US.
10X Genomics Inc (TXG) is a health information services company listed on NASDAQ.
Latest reported OGN revenue for 2026-06-30 was $3.02B. Net income was $254.0M. OGN currently screens at market cap $2.52B and trailing P/E 3.4.
Latest reported TXG revenue for 2026-06-30 was $301.9M. Net income was -$31.4M. TXG currently screens at market cap $4.08B.
OGN currently screens at market cap $2.52B and trailing P/E 3.4. TXG currently screens at market cap $4.08B.
Not investment advice. Open the OGN and TXG stock pages for the full models.
Not investment advice.